Vivani Medical VANI Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Income Loss by Business | ||||||
| Biopharm Division | -$24.52M-14.3% | -$24.15M-13.6% | -$23.48M-13.0% | -$23.02M-12.8% | -$21.45M-3.9% | |
| Other Nonoperating Income Expense by Business | ||||||
| Biopharm Division | $910K-29.2% | $823K-38.9% | $1.35M+350% | $1.28M+942% | $1.29M+53.8% | |
| Operating Expenses by Business | ||||||
| Biopharm Division | $25M— | $25M— | —— | —— | —— | |
| Total Assets by Business | ||||||
| Biopharm Division | $133.6M— | $126.4M— | —— | —— | —— | |
| Other General And Administrative Expense by Business | ||||||
| Biopharm Division | $909K+6.9% | $784K-3.6% | $795K-2.6% | $866K+8.0% | $850K+1.9% | |
| Operating Lease Expense by Business | ||||||
| Biopharm Division | $4.28M+3.8% | $4.21M+5.4% | $4.23M+8.0% | $4.27M+10.6% | $4.12M+4.9% | |
| Labor And Related Expense by Business | ||||||
| Biopharm Division | $10.41M+3.7% | $10.28M+2.2% | $10.07M+0.7% | $10.13M+3.0% | $10.04M+2.6% | |
| Depreciation And Amortization by Business | ||||||
| Biopharm Division | $441K+14.5% | $410K+8.5% | $390K+7.5% | $388K+14.0% | $385K+19.5% | |
| Professional Services And Insurance Expense by Business | ||||||
| Biopharm Division | $4.65M+3.1% | $4.91M+6.8% | $5.17M+15.3% | $4.96M+9.3% | $4.51M-0.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Vivani Medical break its business down?
- Vivani Medical (VANI) reports net income loss by business across 3 parts — Biopharm Division, Neuromodulation Division and Neurostimulation Division. Each is extracted from the segment footnotes and tracked over time.
- Where does Vivani Medical's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Vivani Medical's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.